Dolutegravir/rilpivirine
| Combination of | |
|---|---|
| Dolutegravir | HIV integrase strand transfer inhibitor (INSTI) |
| Rilpivirine | HIV nonnucleoside reverse transcriptase inhibitor (NNRTI) |
| Clinical data | |
| Trade names | Juluca |
| AHFS/Drugs.com | Monograph |
| License data | |
| Pregnancy category |
|
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| UNII | |
| KEGG | |
Dolutegravir/rilpivirine, sold under the brand name Juluca, is a fixed-dose combination of antiretroviral drugs for the treatment of HIV/AIDS.[3] It contains the medicines dolutegravir and rilpivirine.[3] It is taken by mouth daily with food.[3]
The most common adverse reactions (of all severity grades) are diarrhea and headache.[3]
Dolutegravir/rilpivirine was approved for use in the United States in November 2017[3][4][5] and for use in the European Union in May 2018.[6]
References
- ^ a b "Dolutegravir / rilpivirine (Juluca) Use During Pregnancy". Drugs.com. 7 January 2020. Retrieved 25 March 2020.
- ^ "Juluca 50 mg/25 mg film-coated tablets - Summary of Product Characteristics (SmPC)". (emc). 25 February 2020. Retrieved 25 March 2020.
- ^ a b c d e "Juluca- dolutegravir sodium and rilpivirine hydrochloride tablet, film coated". DailyMed. 24 October 2019. Retrieved 25 March 2020.
- ^ "Drug Approval Package: Juluca (dolutegravir and rilpivirine)". U.S. Food and Drug Administration (FDA). 29 June 2018. Retrieved 25 March 2020.
- ^ "Juluca: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Retrieved 25 March 2020.
- ^ "Juluca EPAR". European Medicines Agency (EMA). 11 February 2019. Retrieved 25 March 2020.
External links
- "Dolutegravir mixture with rilpivirine". Drug Information Portal. U.S. National Library of Medicine.
 | This antiinfective drug article is a stub. You can help Wikipedia by expanding it. |